Frank is a business journalist with more than a decade of experience covering various aspects of technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. Frank has a bachelor’s degree in history from Carleton College and a master’s degree in public affairs reporting from the University of Illinois Springfield.
Biotech financing is a cyclical thing. Two years ago, the IPO window was unlatched but a number of companies ended up withdrawing their stock offerings. Others that pushed their IPOs through... Read more »
The window for biotech IPOs remains wide open and six more companies have charged through it, raising more than $568 million in the span of 24 hours.
The first was Eidos... Read more »
Like a good cup of coffee, Seattle’s life sciences ecosystem is a balanced blend of complementary parts: research to find the underpinnings of disease, and information technology that helps scientists make... Read more »
Emulate, a Boston-based startup that has developed small laboratory chips intended to replace the animal tests used in pharmaceutical research, has raised $36 million in financing.
The Series C round of... Read more »
[Updated, 6/19/18, 4:20 p.m. See below.] Hearing loss affects millions of Americans, but so far, drug companies have not yet brought treatments to the market. Decibel Therapeutics aims to... Read more »
Teva Pharmaceutical’s bid to add a new therapeutic application for its experimental migraine-prevention drug has faltered in a late-stage study.
The source of your eye discomfort might be cradled in your hands. If you’re like many people, your eyes spend much of the day fixed on digital displays. Before reading this,... Read more »
Biogen has yet to make the big, transformative buyout Wall Street investors have hoped for. But it continues to place small bets to build up its neurology pipeline. The latest is... Read more »
Nimbus Therapeutics’ drugs have already found new homes with larger companies that aim to develop them into potential treatments for autoimmune and liver diseases. Selling its discoveries was a goal for... Read more »
Eli Lilly won regulatory approval for its rheumatoid arthritis drug Friday, nearly 14 months after the FDA rejected the once-daily pill due to safety concerns. But the approval comes with... Read more »
As Amgen approached an FDA decision last month for its migraine-prevention treatment, concern mounted that the drug would come at premium. In setting a price thousands of dollars less than... Read more »
For the next five days, the oncology community’s attention will focus on Chicago. The Windy City is the home for the American Society of Clinical Oncology’s annual meeting, and it kicks... Read more »
One way to understand the role genes play in disease is to think of the cells in our bodies as electronic circuits. The signaling pathways that either turn a cell’s genes... Read more »
[Updated 5/31/18, 10:13 a.m. See below.] A Vertex Pharmaceuticals partnership with CRISPR Therapeutics to test a genetically engineered therapy as a treatment for patients who have sickle cell disease... Read more »
Avrobio and Eidos Therapeutics, rare disease drug developers on opposite sides of the country, have filed for initial public offerings, each company aiming to raise cash to finance more clinical tests... Read more »
Growing up in China, Zhi Hong saw the healthcare challenges of his homeland firsthand. Despite the country’s economic strides, life science innovation there lags advances made in the West, he says.... Read more »
Seattle’s innovation economy has dual identities: the technology sector that develops the hardware and software that comprise our increasingly digital lives, and the biotechnology sector that is searching for new ways... Read more »
For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers... Read more »
© 2007-2018, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.